3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
1
Liver Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
22
Bevacizumab
15
pembrolizumab
10
durvalumab
7
Nivolumab
7
Ipilimumab
6
Drug Therapy
6
atezolizumab
5
Talaporfin
5
spartalizumab
4
regorafenib
4
lenvatinib
4
derazantinib
3
Ramucirumab
3
Photochemotherapy
3
Leucovorin
3
Injections
3
Fluorouracil
3
Doxorubicin
3
tremelimumab
2
toripalimab
2
seocalcitol
2
relatlimab
2
phosphomannopentaose sulfate
2
liposomal doxorubicin
2
exatecan
2
cabozantinib
2
brivanib
2
Phototherapy
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Liver Neoplasms
×
Cell- and Tissue-Based Therapy
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled